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Abstract: Cardiovascular disease (CVD) accounts for in excess of 930,000 deaths in the United 
States each year. Risk factors for CVD often co-exist. Studies estimate that over half of the 
hypertensive population also has dyslipidemia. Observational data suggest that fewer than 10% 
of patients attain recommended therapeutic targets for both conditions. A variety of patient, 
regimen and system characteristics have been associated with the risk for non-adherence. Poly-
pharmacy and complex drug regimens are associated with poor patient adherence and thus the use 
of ﬁ  xed-dose combination therapies, may improve adherence by reducing the pill burden. The 
ﬁ  xed-dose combination of amlodipine/atorvastatin offers a convenient and effective approach 
to manage two important CVD risk factors. The combination of amlodipine/atorvastatin has 
a synergistic effect. The half-life of both agents facilitates once-daily dosing and both can be 
administered at any time of the day with or without food. Amlodipine/atorvastatin combined 
pill can be used to initiate both agents or patients can be switched directly from single-agent 
therapy with one or both agents. The convenience of single-pill amlodipine/atorvastatin has the 
potential to improve patient adherence and the management of cardiovascular risk in selected 
patients, thereby improving clinical outcomes.
Keywords: amlodipine/atorvastatin, cardiovascular disease, drug combination, adherence, 
poly-pharmacy
Introduction
Cardiovascular disease (CVD) accounts for in excess of 930,000 deaths and 
US$350 billion in direct medication costs and loss of productivity in the United States 
each year.1 Risk factors for CVD often co-exist. For example, in a retrospective study 
among the general veteran population (mainly males) in the United States, 30.7% had 
both hypertension (HTN) and dyslipidemia (DL).2 Clinical studies have demonstrated 
a link between HTN and other metabolically linked risk factors (including metabolic 
X syndrome)3 and various studies estimate that over half of the hypertensive population 
also has DL.4 It is also clear that CVD risk factors tend to increase the total or absolute 
CVD risk in a multiplicative rather than additive manner.5 Thus individual treatment 
strategies should be based on absolute CVD risks, determined by synergistic effect of 
all cardiovascular risk factors present, rather than on individual risk factors.6 Thus in 
hypertensive patients at high cardiovascular risk, the strategy is to include two or more 
antihypertensive (AH) agents for blood pressure control and adding concomitant lipid 
lowering, 3-hydroxy-3-methylglutaryl co enzyme A reductase inhibitor (HMG-Co-A R 
or statin) therapy for CVD risk reduction.7,8
Although the importance of treating HTN and DL is well established in treat-
ment guidelines, the current rate of control of these risk factors is unsatisfactory.9 
United States epidemiological data have indicated that less than 5% of patients with Patient Preference and Adherence 2009:3 62
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concomitant HTN and DL were at goal for both conditions.10 
The reasons for this are not clear, but may include failure to 
treat adequately and poor patient adherence.11 Poly-pharmacy 
and complex drug regimens are associated with poor patient 
adherence and thus the use of ﬁ  xed-dose combination thera-
pies, may improve adherence by reducing the pill burden.12 
Indeed, recent data have shown that ﬁ  xed-dose combination 
therapies improve patient adherence compared with the co-
administration of single-agent formulation13 and that good 
adherence to drug therapy is associated with positive health 
outcomes.14
Deﬁ  nition
Adherence Is deﬁ  ned as behavior that follows the recom-
mendations of a health care provider or degree of prescription 
ﬁ  lling in a given interval.
Compliance is deﬁ  ned as the extent to which a person 
follows a doctor’s order.
Determinants of adherence
A variety of patient, regimen and system characteristics have 
been associated with the risk for non-adherence (Table 1). 
Some patient characteristics include age, sex, race and 
presence of chronic diseases, like diabetes and depression. 
In one study there was signiﬁ  cant disparity in persistence 
among Black and other non-White races which is of particu-
lar concern because Black and Mexican Americans have a 
higher prevalence of CVD than Whites.15 Older patients are 
1.03 times as likely to be adherent compared with younger 
patients, while males were 1.42 times more likely to be 
adherent compared with females.16
A history of stroke, congestive heart failure and diabetes 
predict better persistence. By contrast those who had 
myocardial infarction after starting AH/DL therapy were 
signiﬁ  cantly less likely to continue with their medication 
following the event.17 Patients treated for depression were 
less likely to persist in AH/DL medication use, suggesting 
that depressive symptoms correlate with poor persistence 
with medication use.18
Adherence declines most rapidly during the first 
6 months of concomitant AH and DL therapy, suggesting 
the importance of early interventions to maintain or improve 
adherence.19 Similarly, adherence is best when AH and DL 
therapies are initiated on or about the same time, suggesting 
beneﬁ  t from concomitant initiation of therapy to treat these 
two CVD risk factors.
The number of other medications that a patient is already 
taking is strongly and inversely associated with adher-
ence with concomitant therapy.20 Cost pressure also has a 
substantial inﬂ  uence on the prescription-taking attitude of 
patients, especially older patients. They may simply not ﬁ  ll 
the prescription, skip doses or take smaller doses to make 
the prescription last longer.21 Further, patients with more 
outpatient visits during the baseline period are more adherent 
than patients with fewer visits. Patients who had undergone a 
cardiovascular procedure or who had been hospitalized were 
more adherent, but patients who had at least one emergency 
department visit were less likely to be adherent than those 
who had not had an emergency visit. Patients who ﬁ  lled their 
medication prescription via mail order were more likely to be 
adherent than those who used retail pharmacy stores.22
Need for adherence to modify 
cardiovascular risk factors
Current guidelines for the management of HTN and DL have 
focused on the need to set blood pressure and lipid targets 
dependent on a patient’s overall level of cardiovascular 
risk.23,24 However, observational data suggest that fewer than 
10% of patients attain recommended therapeutic targets for 
both conditions.25 In clinical practice, long-term adherence 
and persistence with prescribed drug therapy are poor. Of all 
the written prescriptions, 14% are never ﬁ  lled and another 
13% are ﬁ  lled but never taken.26 Among patients who actually 
initiate therapy with HMG-Co-A reductase inhibitor or statin, 
observational studies have reported 1-year discontinuation 
rates of 15% to 60% depending on the patient population and 
practice settings.27,28 Similar trends have been observed with 
AH medications. During the ﬁ  rst year of AH therapy, it is 
noted that the average patient had ﬁ  lled AH prescription less 
Table 1 Determinants of non-adherence and poor persistence
1. Patient  characteristics:
  Female
    Age under 45 years
    Age over 75 years
  Low  socio-economic  status
  Non-White
    Comorbidity: dementia, depression, myocardial infarction after statin 
or antihypertensive use
    Asymptomatic/feeling in good health
2. Regimen  characteristics
  Multiple  daily  dosing
  Multiple  drug  regimens
3. System  characteristics
  Long  waiting  time
  Lack  of  insurance
  Medication  costPatient Preference and Adherence 2009:3 63
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than 50% of the time and 1 in 5 patients exhibit compliance 
sufﬁ  cient to obtain the therapeutic beneﬁ  ts observed in 
clinical trials.29
Patients with lower adherence are also responsible for 
substantially greater health care costs than are patients with 
good adherence. In one study, even accounting for savings 
in drug costs, patients who took less than 20% of their lipid 
lowering medications had more than US$3,000 greater yearly 
health care costs than patients with 80% adherence.30
The under-recognition of medication non-adherence 
can have adverse consequences.31 For example, patients 
may have poor blood pressure control related to medication 
non-adherence. However, the clinician may attribute poor 
blood pressure control to therapeutic ineffectiveness and may 
increase dose of current medication or add more medications 
to the regimen.
On the other hand, lack of patient adherence to multiple 
therapies is common and is associated with poor clinical 
outcomes.32 As a result, concerns that increasing a patient’s 
bill burden will decrease adherence may discourage physi-
cians from adding further medication to a patients’ existing 
regimen, despite potential therapeutic beneﬁ  ts.33,34 Thus better 
patient adherence is a cornerstone for therapeutic success and 
achievement of target goals in order to modify risk factors 
and decrease morbidity associated with CVD.
Therefore, medication non-adherence should be routinely 
assessed by the physician. Once identiﬁ  ed, clinicians should 
explore the reasons for the non-adherence and implement 
measures to improve adherence – the most simple of which 
is simplifying therapeutic regimens.
Interventions to improve adherence; 
simplifying the drug regimen
There are a number of interventions to improve patient adher-
ence. One of the simplest ways to improve adherence is to 
simplify the drug regimen by adding combination therapy. 
Compared with single-agent therapy, combination therapy is 
associated with increased compliance, greater response and 
lower cost (Table 2). A study within a large managed care 
population (n = 8406) showed that patients who initiated 
both AH and DL therapies within 30 days of each other were 
more likely to be adherent to both drugs over time.35 After 
4 months, patients who were prescribed AH and DL therapy 
together were 5% to 24% more adherent to therapy than those 
who were prescribed AH and DL therapy separately.
Several studies have explored the role of single-pill 
combinations in improving adherence rates. In particular, 
the single-pill combination of atorvastatin and amlodipine 
(Caduet®, Pﬁ  zer, Inc) has provided a unique opportunity 
to explore the issue of adherence in individuals with both 
hypertension and dyslipidemia.36 Amlodipine besylate is a 
dihydropyidine calcium channel blocker (CCB) used for 
treatment of hypertension and both vaso-spastic and chronic 
stable angina.37 Atorvastatin is a HMG-Co-A reductase 
inhibitor that has been shown to be an effective and safe 
treatment for dyslipidemia and is also effective in reducing 
the rate of coronary events and revascularization procedure 
in patients with multiple cardiovascular risk factors.38,39
The combination of amlodipine and atorvastatin has a 
synergistic effect. Amlodipine in clinical studies has dem-
onstrated some antiatherosclerotic properties.40 A potential 
synergistic and dose-dependent increase in nitric oxide (NO) 
has been observed with this combination (NO is a potent 
arterial vasodilator).41 Additional synergistic effects observed 
with this combination include improved arterial wall com-
pliance42 and decrease in insulin resistance.43 The pharma-
cokinetic and pharmacodynamic properties of amlodipine 
and atorvastatin make them well suited for combination in 
a single pill to manage cardiovascular risk.44,45 The half-life 
of both agents facilitates once-daily dosing and both can be 
administrated at any time of the day with or without food. 
Another advantage of this combination is its availability in 
a variety of combination dosage (eg, 2.5/10, 2.5/20, 2.5/40, 
5/10, 5/20), thus making it easier for the clinician to escalate 
the dose of one agent to achieve target therapeutic blood 
pressure and cholesterol levels.
The co-administration of amlodipine and atorvastatin 
has been demonstrated to be safe and effective at lowering 
both blood pressure and low density lipoprotein cholesterol 
(LDL-C) levels in patients with concomitant HTN and DL.
Amlodipine/atorvastatin combined pill can be used to 
initiate both agents or patients can be switched directly from 
single-agent therapy with one or both agents.46
The GEMINI study was a 14-week open-label study 
designed to simulate real world clinical practice.47 
Table 2 Advantage of ﬁ  xed-dose combination therapy
Increased compliance, simpliﬁ  ed titration and convenience of use
Additive or synergistic effects
Enhancing effects in speciﬁ  c populations
Attenuation in adverse events
Improved overall results
Greater response
Lower cost
Availability in a variety of dosing combinations, making it easy to escalate dose 
of one medicine while keeping same dose for other medicine (Caduet)Patient Preference and Adherence 2009:3 64
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Almost 60% of all patients and more than 75% of patients 
without CVD or CVD risk equivalents met target levels for 
both blood pressure and LDL-C after a 14-week period and 
3 titration visits.
The JEWEL Program consisted of 2 similar 16-week 
studies (JEWEL I in UK and Canada, JEWEL II in Europe) 
involving a total of 2219 patients (intent to treat population).48 
Eight ﬁ  xed doses of amlodipine/atorvastatin were administered 
to establish country-speciﬁ  c target reduction in blood pressure 
and LDL-C. At end point, the percentage of patients who 
achieved both their target blood pressure and LDL-C were 
62.9% in JEWEL I and 50.6% in JEWEL II, respectively.49
Similar results were noted in RESPOND50 (conducted 
in the US), GEMINI-AALA51 (conducted in Asia Paciﬁ  c, 
Middle East and Africa) and CAPABLE52 (conducted in an 
African-American population in the US) trials (Table 3).
In observational studies, similar results have been 
observed. In one study, 5 cohorts representing 4703 patients 
were observed depending on their CCB and statin therapy53 
(1. amlodipine/atorvastatin [single pill]; 2. amlodipine + 
atorvastatin; 3. amlodipine + other statin [not including 
atorvastatin]; 4. atorvastatin + other CCB [not includ-
ing amlodipine]; 5. other CCB + other statin [not including 
atorvastatin or amlodipine]).
Adherence was measured during a 6-month post-baseline 
period as proportion of days covered (PDC), based on the 
days that both antihypertensive and lipid-lowering drugs were 
supplied. Patients were considered to be adherent if their PDC 
was 80%. The probability of achieving adherence using 
single-pill amlodipine/atorvastatin was 1.95-times greater 
than with the parent compounds amlodipine and atorvastatin 
administered separately (p  0.0001), and ranged from 2.06- 
to 3.10-times greater than for any of the other CCB and statin 
regimens studied (p  0.0001). For the additional 1-year 
analysis, patients receiving amlodipine/atorvastatin were 
2.41- to 3.50-times more likely to achieve adherence than 
patients on a 2-pill CCB and statin regimen. Furthermore, 
patients taking single-pill amlodipine/atorvastatin were less 
likely to discontinue therapies compared with those taking the 
parent compounds or other CCB and statin combinations.
Conclusion
The overall goal in the prevention of CVD is to improve 
the multivariate risk proﬁ  les, rather than treating single risk 
factors. Given the signiﬁ  cant burden of non-adherence in 
society, better strategies are required to improve medication 
adherence so that all patients may beneﬁ  t from evidence-based 
therapies. A combination of patient-focused, physician-
focused and system-focused interventions work best.
The ﬁ  xed-dose combination of amlodipine/atorvastatin 
offers a convenient and effective approach to manage two 
important CVD risk factors. The combination is generally 
well tolerated and bioequivalent to amlodipine and atorvas-
tatin given alone. The convenience of single-pill amlodipine/
atorvastatin has the potential to improve patient adherence 
and the management of cardiovascular risk in selected 
patients, thereby improving clinical outcomes.
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